Pharmaron Beijing Co Ltd
SZSE:300759
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
18.08
36.42
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Pharmaron Beijing Co Ltd
Pharmaron Beijing Co Ltd
Total Receivables
Pharmaron Beijing Co Ltd
Total Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Pharmaron Beijing Co Ltd
SZSE:300759
|
Total Receivables
¥2.9B
|
CAGR 3-Years
23%
|
CAGR 5-Years
25%
|
CAGR 10-Years
N/A
|
|
|
WuXi AppTec Co Ltd
SSE:603259
|
Total Receivables
¥10.1B
|
CAGR 3-Years
23%
|
CAGR 5-Years
29%
|
CAGR 10-Years
N/A
|
|
|
WuXi Biologics (Cayman) Inc
HKEX:2269
|
Total Receivables
¥6.8B
|
CAGR 3-Years
13%
|
CAGR 5-Years
41%
|
CAGR 10-Years
N/A
|
|
|
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
|
Total Receivables
¥4.3B
|
CAGR 3-Years
31%
|
CAGR 5-Years
31%
|
CAGR 10-Years
33%
|
|
|
M
|
MGI Tech Co Ltd
SSE:688114
|
Total Receivables
¥931.5m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
W
|
WuXi XDC Cayman Inc
HKEX:2268
|
Total Receivables
¥985.8m
|
CAGR 3-Years
177%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Pharmaron Beijing Co Ltd
Glance View
Pharmaron Beijing Co Ltd is a CN-based company operating in Life Sciences Tools & Services industry. The company is headquartered in Beijing, Beijing and currently employs 14,923 full-time employees. The company went IPO on 2019-01-28. Pharmaron Beijing Co., Ltd. is a China-based company that provides research and manufacturing services throughout the discovery, development and manufacturing spectrum for small molecule drugs, cell therapies and gene therapies as well as providing testing services for medical devices and clinic research. The firm has four segments. The Laboratory Services segment includes laboratory chemistry, drug metabolism and pharmacokinetics/absorption, distribution, metabolism and excretion, biology, safety assessment and discovery of biologics services. The Clinical Development Services segment includes clinical research, site management organization, regulatory bioanalysis and radiolabelled sciences service. The Chemistry, Manufactory and Control Services segment includes process development and manufacturing, material science/pre-formulation, formulation development and manufacturing and analytical development and commercial manufacturing services. The firm also operates Others segment.
See Also
What is Pharmaron Beijing Co Ltd's Total Receivables?
Total Receivables
2.9B
CNY
Based on the financial report for Jun 30, 2024, Pharmaron Beijing Co Ltd's Total Receivables amounts to 2.9B CNY.
What is Pharmaron Beijing Co Ltd's Total Receivables growth rate?
Total Receivables CAGR 5Y
25%
Over the last year, the Total Receivables growth was 10%. The average annual Total Receivables growth rates for Pharmaron Beijing Co Ltd have been 23% over the past three years , 25% over the past five years .
You don't have any saved screeners yet
